Cargando…

Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft

OBJECTIVES: Osteochondral allograft (OCA) transplantation is effective for treatment of large articular defects in the knee, hip, ankle, and shoulder of athletes. While success after OCA transplantation is good, one mechanism of failure involves inintegration of OCA bone into recipient bone. Because...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, James L., Baumann, Charles A., Stoker, Aaron M., Monibi, Farrah, Walden, Nicole L., Crist, Brett D., Kfuri, Mauricio, Smith, Matthew Jared, Stannard, James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565016/
http://dx.doi.org/10.1177/2325967117S00446
_version_ 1783258346095116288
author Cook, James L.
Baumann, Charles A.
Stoker, Aaron M.
Monibi, Farrah
Walden, Nicole L.
Crist, Brett D.
Kfuri, Mauricio
Smith, Matthew Jared
Stannard, James P.
author_facet Cook, James L.
Baumann, Charles A.
Stoker, Aaron M.
Monibi, Farrah
Walden, Nicole L.
Crist, Brett D.
Kfuri, Mauricio
Smith, Matthew Jared
Stannard, James P.
author_sort Cook, James L.
collection PubMed
description OBJECTIVES: Osteochondral allograft (OCA) transplantation is effective for treatment of large articular defects in the knee, hip, ankle, and shoulder of athletes. While success after OCA transplantation is good, one mechanism of failure involves inintegration of OCA bone into recipient bone. Because the OCA bone is devoid of viable cells and blood supply at implantation, and is allogeneic, integration is dependent upon cellular repopulation and neovascularization via creeping substitution. Enhancing this process using bone marrow aspirate concentrate (BMAC) or platelet rich plasma (PRP) could minimize graft failures and improve patient outcomes. Therefore, this study was designed to test the hypothesis that BMAC would be associated with superior viable osteoprogenitor cell repopulation of OCAs and osteoinductive protein production compared to PRP and saline using an ex vivo model. METHODS: With ACUC approval, BMAC and leukoreduced PRP were processed from BMA (proximal humerus) and whole blood (jugular vein), respectively, of adult dogs using a commercially available system. Femoral condyles were harvested from adult dogs (n=3) immediately after euthanasia for unrelated reasons and preserved using tissue bank protocol. On day 21 of preservation, cylindrical OCAs (8 mm diam x 8 mm depth) were created (n=36; 12/dog), and randomly assigned to treatments: (1) NEG - bone portion of OCA lavaged with 10 ml saline (2) BMAC - bone portion of OCA lavaged, dried, and then saturated with 0.5 ml BMAC (3) PRP - bone portion of OCA lavaged, dried, and then saturated with 0.5 ml PRP. OCAs were cultured for 7 or 14 days (n=6/group/day), media were changed and collected on days 3, 7, and 14 for biomarker analysis. On days 7 and 14, OCAs were evaluated for viable cell colonization and infiltration using Calcein AM staining. To determine if cells were osteoprogenitors, colony forming unit (CFU) analysis was performed using crystal violet staining to determine CFUs/ml for each BMAC and PRP sample. OCA culture media were assessed for alkaline phosphatase (ALP), dickkopf-related protein (DKK), osteoprotegerin (OPG), osteopontin (OPN), adrenocorticotropic hormone (ACTH), bone morphogenic protein-2 (BMP-2), and bone morphogenic protein-7 (BMP-7) using commercially available assays. Data were compared for statistically significance (p≤0.05) differences. RESULTS: For all BMAC OCAs, viable cells were present on the surface and deep areas of the bone at days 7 and 14. Viable cells were not observed in any part of the bone of PRP or NEG OCAs at either time point (Fig). BMAC samples had a significantly higher (p=0.029) CFU/ml compared to PRP. Concentrations of OPG were significantly higher in BMAC and PRP compared to NEG at days 3 (p<0.001) and 7 (p≤0.004). The concentration of DKK was significantly (p=0.038) higher in BMAC compared to NEG at day 3. Concentrations of BMP-2 were significantly higher in BMAC at days 3 (p<0.001) and 7 (p=0.017) and PRP at day 3 (p=0.009) compared to NEG. The concentration of ALP was significantly lower in PRP compared to NEG at day 3 (p=0.03). Concentrations of BMP-7 and OPN were below detectable limits of the assay for all groups and time points. CONCLUSION: BMAC showed superior viable osteoprogenitor cell repopulation of OCAs and osteoinductive protein production compared to PRP and the current standard-of-care (saline). BMAC has potential to enhance integration of osteochondral allograft bone and to improve graft survivorship and patient outcomes.
format Online
Article
Text
id pubmed-5565016
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55650162017-08-24 Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft Cook, James L. Baumann, Charles A. Stoker, Aaron M. Monibi, Farrah Walden, Nicole L. Crist, Brett D. Kfuri, Mauricio Smith, Matthew Jared Stannard, James P. Orthop J Sports Med Article OBJECTIVES: Osteochondral allograft (OCA) transplantation is effective for treatment of large articular defects in the knee, hip, ankle, and shoulder of athletes. While success after OCA transplantation is good, one mechanism of failure involves inintegration of OCA bone into recipient bone. Because the OCA bone is devoid of viable cells and blood supply at implantation, and is allogeneic, integration is dependent upon cellular repopulation and neovascularization via creeping substitution. Enhancing this process using bone marrow aspirate concentrate (BMAC) or platelet rich plasma (PRP) could minimize graft failures and improve patient outcomes. Therefore, this study was designed to test the hypothesis that BMAC would be associated with superior viable osteoprogenitor cell repopulation of OCAs and osteoinductive protein production compared to PRP and saline using an ex vivo model. METHODS: With ACUC approval, BMAC and leukoreduced PRP were processed from BMA (proximal humerus) and whole blood (jugular vein), respectively, of adult dogs using a commercially available system. Femoral condyles were harvested from adult dogs (n=3) immediately after euthanasia for unrelated reasons and preserved using tissue bank protocol. On day 21 of preservation, cylindrical OCAs (8 mm diam x 8 mm depth) were created (n=36; 12/dog), and randomly assigned to treatments: (1) NEG - bone portion of OCA lavaged with 10 ml saline (2) BMAC - bone portion of OCA lavaged, dried, and then saturated with 0.5 ml BMAC (3) PRP - bone portion of OCA lavaged, dried, and then saturated with 0.5 ml PRP. OCAs were cultured for 7 or 14 days (n=6/group/day), media were changed and collected on days 3, 7, and 14 for biomarker analysis. On days 7 and 14, OCAs were evaluated for viable cell colonization and infiltration using Calcein AM staining. To determine if cells were osteoprogenitors, colony forming unit (CFU) analysis was performed using crystal violet staining to determine CFUs/ml for each BMAC and PRP sample. OCA culture media were assessed for alkaline phosphatase (ALP), dickkopf-related protein (DKK), osteoprotegerin (OPG), osteopontin (OPN), adrenocorticotropic hormone (ACTH), bone morphogenic protein-2 (BMP-2), and bone morphogenic protein-7 (BMP-7) using commercially available assays. Data were compared for statistically significance (p≤0.05) differences. RESULTS: For all BMAC OCAs, viable cells were present on the surface and deep areas of the bone at days 7 and 14. Viable cells were not observed in any part of the bone of PRP or NEG OCAs at either time point (Fig). BMAC samples had a significantly higher (p=0.029) CFU/ml compared to PRP. Concentrations of OPG were significantly higher in BMAC and PRP compared to NEG at days 3 (p<0.001) and 7 (p≤0.004). The concentration of DKK was significantly (p=0.038) higher in BMAC compared to NEG at day 3. Concentrations of BMP-2 were significantly higher in BMAC at days 3 (p<0.001) and 7 (p=0.017) and PRP at day 3 (p=0.009) compared to NEG. The concentration of ALP was significantly lower in PRP compared to NEG at day 3 (p=0.03). Concentrations of BMP-7 and OPN were below detectable limits of the assay for all groups and time points. CONCLUSION: BMAC showed superior viable osteoprogenitor cell repopulation of OCAs and osteoinductive protein production compared to PRP and the current standard-of-care (saline). BMAC has potential to enhance integration of osteochondral allograft bone and to improve graft survivorship and patient outcomes. SAGE Publications 2017-07-31 /pmc/articles/PMC5565016/ http://dx.doi.org/10.1177/2325967117S00446 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc-nd/3.0/ This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For reprints and permission queries, please visit SAGE’s Web site at http://www.sagepub.com/journalsPermissions.nav.
spellingShingle Article
Cook, James L.
Baumann, Charles A.
Stoker, Aaron M.
Monibi, Farrah
Walden, Nicole L.
Crist, Brett D.
Kfuri, Mauricio
Smith, Matthew Jared
Stannard, James P.
Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft
title Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft
title_full Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft
title_fullStr Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft
title_full_unstemmed Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft
title_short Comparison of Platelet Rich Plasma and Bone Marrow Aspirate Concentrate for Osteoprogenitor Cell Retention and Osteoinductive Potential for Osteochondral Allograft
title_sort comparison of platelet rich plasma and bone marrow aspirate concentrate for osteoprogenitor cell retention and osteoinductive potential for osteochondral allograft
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565016/
http://dx.doi.org/10.1177/2325967117S00446
work_keys_str_mv AT cookjamesl comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT baumanncharlesa comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT stokeraaronm comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT monibifarrah comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT waldennicolel comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT cristbrettd comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT kfurimauricio comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT smithmatthewjared comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft
AT stannardjamesp comparisonofplateletrichplasmaandbonemarrowaspirateconcentrateforosteoprogenitorcellretentionandosteoinductivepotentialforosteochondralallograft